

PRIOR AUTHORIZATION REQUEST FORM EOC ID: Enbrel (etanercept) 49 Phone: 1-866-315-7587 Fax to: 1-800-310-9071

CarePlus manages the pharmacy drug benefit for your patient. Certain requests for prior authorization require additional information from the prescriber. Please provide the following information and fax this form to the number listed above. Information left blank or illegible may delay the review process.

Patient name:		Prescriber name:	
Member/subscriber number:		Fax:	Phone:
Patient date of birth:		Office contact:	
Group number:		NPI:	Tax ID:
Address:		Address:	
City, state ZIP:		City, state ZIP:	
		Specialty/facility nam	e (if applicable):
Drug name:	Exped	ited/exigent/urgent	
Directions/SIG:	By checking this box, I certify an expedited/exigent/urgent review is required. The member has a health condition that may seriously jeopardize his/her life or ability		
Quantity:	to regain maximum function. (Please include explanation of exigency in the space below.)		
(Please note: All reviews will be processed with generic Please attach pertinent medical history or informati Q1. Please provide diagnosis: *	-	-	
Q1. Please provide diagnosis: *			
Active psoriatic arthritis			
Moderate to severe, chronic plaque psoriasis			
Moderately to severely active polyarticular juvenile idiopathic arthritis			
Moderately to severely active rheumatoid	-		
Other (please specify)			
Q2. Please provide ICD Diagnostic Codes:			
Q3. Is the request for a reauthorization?			
☐ Yes ☐ No			
Q4. Has the patient had prior therapy, contraind apply)	ication or int	olerance with any of	the following: (Please mark all that
🗌 DMARD (e.g. leflunomide, sulfasalazine, l	hydroxychloi	roquine, methotrexat	e, or cyclosporine)
□ NSAIDs (non-steroidal anti-inflammatory o	drug) (e.g. ib	ouprofen, meloxicam,	naproxen)



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Enbrel (etanercept) 49

Phone: 1-866-315-7587 Fax back to: 1-800-310-9071

Patient Name:

Prescriber Name:

Oral systemic treatments (e.g. acitretin, methotrexate, hydroxycarbamide, cyclosporine, sulfasalazine)

None of the above

Q5. Please provide previous therapies used with start/end dates and reason for discontinuing drug(s) that would be pertinent to the review of the drug requested:

Prescriber signature

Date

I declare under penalty of perjury under the laws of the United States of America that the information provided is true and correct. This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately. 2746ALL1216-A H109_PHAPrvdPAForm2016